In agreement with the view that limiting post-stroke inflammation will decrease neuronal death or promote neurological recovery, IFN-β has been put forward as a candidate drug for the treatment of stroke (National Institute of Neurological Disorders and Stroke-sponsored phase I clinical trial). Here, IFNB1 is linked to Stroke.